Plain-English translation of NCT05245500 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mesothelioma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is the first human trial of a medication called , designed to treat advanced cancers that have a particular genetic change (a missing MTAP gene). Researchers are testing different doses and forms of the medication to find what works best and is safest. Early evidence suggests the treatment may help fight these hard-to-treat cancers.
Many advanced cancers have this specific genetic deletion, but there are very few treatment options available. This trial exists to see if this new medication can be a helpful option for people facing these difficult diagnoses.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth (as a capsule or tablet) on a regular schedule determined by the research team. You will have frequent clinic visits early on to check your safety and how your body responds, including blood tests and scans. You will also need to have tumor biopsies at the start and during the trial so researchers can study how the medication is affecting your cancer cells. The trial is designed to last as long as the treatment is helping you and you're tolerating it well.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States